AstraZeneca plc (AZN)

NASDAQ: AZN · IEX Real-Time Price · USD
1.22 (1.93%)
At close: May 19, 2022 4:00 PM
1.08 (1.68%)
After-hours:May 19, 2022 7:54 PM EDT
Market Cap204.13B
Revenue (ttm)41.49B
Net Income (ttm)-1.06B
Shares Out3.16B
EPS (ttm)-0.36
PE Ration/a
Forward PE18.59
Dividend$1.42 (2.19%)
Ex-Dividend DateFeb 24, 2022
Previous Close63.32
Day's Range63.15 - 64.79
52-Week Range53.63 - 71.70
Price Target69.44 (+7.6%)
Earnings DateApr 29, 2022

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere...

IPO DateMay 12, 1993
CEOPascal Soriot
Stock ExchangeNASDAQ
Ticker SymbolAZN
Full Company Profile

Financial Performance

In 2021, AstraZeneca's revenue was $37.42 billion, an increase of 40.58% compared to the previous year's $26.62 billion. Earnings were $112.00 million, a decrease of -96.50%.

Financial Statements

Analyst Forecast

According to 39 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is 69.44, which is an increase of 7.59% from the latest price.

Price Target
(7.59% upside)
Analyst Consensus: Buy
Stock Forecasts


AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies

AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.

1 day ago - Zacks Investment Research

5 Stocks to Buy for the Coming Recession

Each of these stocks to buy are low-beta stocks with attractive dividend yields to help endure a recession. The post 5 Stocks to Buy for the Coming Recession appeared first on InvestorPlace.

Other symbols:JNJLMTTWMT
1 day ago - InvestorPlace

Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca

MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nas...

3 days ago - Business Wire

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination ...

CHENGDU, China and SEATTLE and LONDON , May 13, 2022 /PRNewswire/ -- BAILI-BIOPHARMACEUTICAL CO., LTD. ("Baili") and its wholly owned subsidiary, SystImmune, Inc ("SystImmune"), announced today that it ...

6 days ago - PRNewsWire

Is This Vaccine Stock in Trouble -- or Ready for a Rebound?

Inovio may be at a turning point.

6 days ago - The Motley Fool

3 Top Biotech Stocks to Buy Right Now

These three pharma stocks each pay market-beating dividends to shareholders.

Other symbols:PFESNY
1 week ago - The Motley Fool

3 Nasdaq 100 Stocks to Buy Hand Over Fist in May

These fast-paced stocks are plain-as-day bargains.

Other symbols:AVGOBIDU
1 week ago - The Motley Fool

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

2 weeks ago - Business Wire

AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates

AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.

2 weeks ago - Zacks Investment Research

AstraZeneca CEO: ‘each of our businesses grew a lot in Q1'

AstraZeneca plc (LON: AZN) on Friday said vaccine contracts helped its Q1 financial results. Moving forward, however, it expects COVID-related sales to sink by 21% to 25%.

2 weeks ago - Invezz

We expect slight decline in China due to price pressures, AstraZeneca CEO says

Pascal Soriot discusses the company's performance in China and the prospect for future M&A.

2 weeks ago - CNBC International TV

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines a...

2 weeks ago - Benzinga

AstraZeneca revenue surges $11.39 billion, but sees COVID vaccine sales decline

AstraZeneca PLC said Friday that it expects sales of its Covid-19 medicines, including its vaccine, to decline by a low-to-mid twenties percentage during the year, but reported higher revenue in the fir...

2 weeks ago - Market Watch

AstraZeneca beats Q1 estimates, keeps 2022 forecasts

(Reuters) -AstraZeneca on Friday beat first-quarter sales and profit expectations and stood by its forecasts for 2022 as newer therapies for kidney disease and rare conditions offset an expected decline...

2 weeks ago - Reuters

Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN

Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.

Other symbols:ABBVBMY
3 weeks ago - Zacks Investment Research

Should You Buy AstraZeneca (AZN) Ahead of Earnings?

AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer

3 weeks ago - Business Wire

Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single priming dose ...

3 weeks ago - Business Wire

AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer

The FDA has accepted for review AstraZeneca Plc's (NASDAQ: AZN) marketing application for tremelimumab as a single priming dose added to Imfinzi (durvalumab) for unresectable hepatocellular carcinoma (H...

3 weeks ago - Benzinga

These Dividend Stocks Are Trouncing the Market -- Are They Still Buys?

Investors don't like these stocks only because of their dividends.

Other symbols:ABBVCVX
3 weeks ago - The Motley Fool

2 Dividend Stocks to Buy and Hold Forever

These two companies have been around a while.

Other symbols:MRK
3 weeks ago - The Motley Fool

2 Charts Big Pharma Investors Need to Understand

The industry's leaders will fight to maintain their ranking over the next few years.

Other symbols:PFE
4 weeks ago - The Motley Fool

AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag

FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).

4 weeks ago - Zacks Investment Research

ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Ce...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received notification of acceptance of the supplemental Biologics License Application ...

1 month ago - Business Wire

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in Chi...

SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a ...

1 month ago - GlobeNewsWire